Drug Details

General Information of the Drug (ID: DR4718)
Name
Primaquin
Synonyms
PRIMAQUINE; 90-34-6; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Primachin; Neo-Quipenyl; Primaquin; Primachinum; Primaquinum; Primaquina; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; SN 13,272; S. N. 13272; WR 2975; (RS)-primaquine; NSC 27296; CHEBI:8405; 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; l-Primaquine; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; NSC27296; NSC-27296; 1,4-Pentanediamine, N(4)-(6-methoxy-8-quinolinyl)-; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; Primachina [DCIT]; Primachina; dl-Primaquine; Primaquine [INN:BAN]; BRN 0019337; Maliride; NSC 27296; Neo-Quipenyl; Primachin; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine; Primaquinum [INN-Latin]; Primaquina [INN-Spanish]; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; (+/-)-Primaquine; CHEMBL506; MLS001334045; (+)-Primaquine; (-)-Primaquine; Kanaprim (TN); Primaquine (INN); CCRIS 4109; HSDB 6516; 4-22-00-05817 (Beilstein Handbook Reference); 57152-58-6; NCGC00178754-06; N~4~-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SMR000875314; EINECS 201-987-2; 6-Methoxy-8-((4-amino-1-methylbutyl)amino)quinoline; Quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; TG1-296; TG1-297; Spectrum_000830; Prestwick0_000476; Prestwick1_000476; Prestwick2_000476; Prestwick3_000476; Spectrum2_000887; Spectrum3_000552; Spectrum4_000484; Spectrum5_001363; Epitope ID:131792; Oprea1_546209; SCHEMBL22207; BSPBio_000612; BSPBio_002223; KBioGR_000967; KBioSS_001310; DivK1c_000806; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SPBio_000674; SPBio_002551; (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; BPBio1_000674; cid_359247; GTPL9952; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy-; DTXSID8023509; BDBM71542; KBio1_000806; KBio2_001310; KBio2_003878; KBio2_006446; KBio3_001723; NINDS_000806; HMS2090J17; BCP29271; ANW-50074; BBL011330; MFCD00598906; STL146416; 1, N4-(6-methoxy-8-quinolinyl)-; AKOS005721199; DB01087; MCULE-1557087031; WLN: T66 BNJ HO1 JMY1&3Z; WR-2975; IDI1_000806; SMP1_000263; NCGC00178754-01; NCGC00178754-02; NCGC00178754-03; AC-23007; AS-30679; NCI60_001035; NCI60_005887; SN-13272; SBI-0051491.P003; AB00053529; FT-0687514; W9302; C07627; D08420; S-4508; AB00053529-11; AB00053529_12; AB00053529_14; N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 598P906; A843518; N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine; Q419834; BRD-A55913614-316-06-2; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (9CI); N-[(S)-4-Amino-1-methylbutyl]-6-methoxy-8-quinolinamine; N4-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine (2 H3PO4); N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine;phosphoric acid; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid; (4-amino-1-methyl-butyl)-(6-methoxy-8-quinolyl)amine;phosphoric acid
    Click to Show/Hide
Molecular Type
Small molecule
Disease Malaria [ICD-11: 1F40] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C15H21N3O
PubChem CID
4908
Canonical SMILES
CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
InChI
1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
InChIKey
INDBQLZJXZLFIT-UHFFFAOYSA-N
CAS Number
CAS 90-34-6
ChEBI ID
CHEBI:8405
TTD Drug ID
D0T1LK
DrugBank ID
DB01087
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Tretinoin      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CDKN1A  Molecule Info 
Pathway MAP
                    In-vivo Model C57BL/6 micemice were transtracheally instilled with 2*106 of Pc organisms in 50 uL sterile PBS.
                    Experimental
                    Result(s)		 All-trans retinoic acid in combination with primaquine clears pneumocystis infection.
Target and Pathway
Target(s) Plasmodium Deoxyribonucleic acid (Malaria DNA)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 008316.
Reference 2 All-trans retinoic acid in combination with primaquine clears pneumocystis infection. PLoS One. 2013;8(1):e53479.
Reference 3 Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107.
 Download Picture         KEGG Link